Abstract:BACKGROUND:The morbidity and treatment costs associated with skin and soft tissue infections (SSTIs) are high. Linezolid and vancomycin are antibiotics that are commonly used in treating skin and soft-tissue infections, specifically those infections due to methicillin-resistant Staphylococcus aureus (MRSA).OBJECTIVES:To compare the effects and safety of linezolid and vancomycin for treating people with SSTIs.SEARCH METHODS:In May 2013 we conducted searches of the following databases: Cochrane Wounds Group Specialised Register; The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations); Ovid EMBASE; and EBSCO CINAHL. We also contacted manufacturers for details of unpublished and ongoing trials. We scrutinised citations within all obtained trials and major review articles to identify any additional trials.SELECTION CRITERIA:We included all randomised controlled trials (RCTs) comparing linezolid with vancomycin in the treatment of SSTIs.DATA COLLECTION AND ANALYSIS:Two review authors independently selected trials, assessed risk of bias and extracted data. The primary outcomes were clinical cure, microbiological cure, and SSTI-related and treatment-related mortality. We performed subgroup analyses according to age, and whether the infection was due to MRSA.MAIN RESULTS:We included nine RCTs (3144 participants). Linezolid was associated with a significantly better clinical (RR 1.09, 95% CI 1.03 to 1.16) and microbiological cure rate in adults (RR 1.08, 95% CI 1.01 to 1.16). For those infections due to MRSA, linezolid was significantly more effective than vancomycin in clinical (RR 1.09, 95% CI 1.03 to 1.17) and microbiological cure rates (RR 1.17, 95% CI 1.04 to 1.32). No RCT reported SSTI-related and treatment-related mortality. There was no significant difference in all-cause mortality between linezolid and vancomycin (RR 1.44, 95% CI 0.75 to 2.80). There were fewer incidents of red man syndrome (RR 0.04, 95% CI 0.01 to 0.29), pruritus (RR 0.36, 95% CI 0.17 to 0.75) and rash (RR 0.27, 95% CI 0.12 to 0.58) in the linezolid group compared with vancomycin, however, more people reported thrombocytopenia (RR 13.06, 95% CI 1.72 to 99.22), and nausea (RR 2.45, 95% CI 1.52 to 3.94) when treated with linezolid. It seems, from the available data, that length of stay in hospital was shorter for those in the linezolid group than the vancomycin group. The daily cost of outpatient therapy was less with oral linezolid than with intravenous vancomycin. Although inpatient treatment with linezolid cost more than inpatient treatment with vancomycin per day, the median length of hospital stay was three days shorter with linezolid. Thus, total hospital charges per patient were less with linezolid treatment than with vancomycin treatment.AUTHORS' CONCLUSIONS:Linezolid seems to be more effective than vancomycin for treating people with SSTIs, including SSTIs caused by MRSA. The available evidence is at high risk of bias and is based on studies that were supported by the pharmaceutical company that makes linezolid. Further well-designed, independently-funded, RCTs are needed to confirm the available evidence.

686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06)

A Phase III Multicentre, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Oral Contezolid Versus Linezolid in Adults with Complicated Skin and Soft Tissue Infections.

Contezolid in complicated skin and soft tissue infection

In Vitro Activity of Contezolid Against Methicillin-Resistant Staphylococcus Aureus, Vancomycin-Resistant Enterococcus, and Strains with Linezolid Resistance Genes from China.

Multicentre evaluation of in vitro activity of contezolid against drug-resistant Staphylococcus and Enterococcus

A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro

Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment

Antibacterial activity of the novel oxazolidinone contezolid (MRX-I) against Mycobacterium abscessus

Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections

Pharmacokinetics and Disposition of Contezolid in Humans—Resolution of a Disproportionate Human Metabolite for Clinical Development

In vivo antibacterial activity of MRX-I, a new oxazolidinone.

Linezolid versus glycopeptides in the treatment of complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials

Comparative effectiveness and safety of six antibiotics in treating MRSA infections: A network meta-analysis

Linezolid versus vancomycin in the treatment of skin and soft tissue infections:meta-analysis of randomised controlled trials

Linezolid and Rifampicin Combination to Combat Cfr-Positive Multidrug-Resistant MRSA in Murine Models of Bacteremia and Skin and Skin Structure Infection

Linezolid Versus Vancomycin for Meticillin-Resistant Staphylococcus Aureus Infection: a Meta-Analysis of Randomised Controlled Trials.

In Vitro Activities Of Tedizolid Compared With Other Antibiotics Against Gram-Positive Pathogens Associated With Hospital-Acquired Pneumonia, Skin And Soft Tissue Infection And Bloodstream Infection Collected From 26 Hospitals In China

Linezolid Versus Vancomycin for Skin and Soft Tissue Infections.

Selection and Characterisation of Staphylococcus Aureus Mutants with Reduced Susceptibility to the Investigational Oxazolidinone MRX-I.

1818. A Network Meta-Analysis of Antibiotic Efficacy for the Treatment of Skin and Soft Tissue Infections

Sensitivity analyses of linezolid against clinical gram-positive cocci isolates in vitro